Assuntos
Ansiolíticos/farmacologia , Biureias/farmacologia , Hipocinesia/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Lipídeos/sangue , Glândulas Suprarrenais/patologia , Animais , Arteriosclerose/metabolismo , Peso Corporal , Colesterol/sangue , Modelos Animais de Doenças , Hipocinesia/patologia , Masculino , Malondialdeído/sangue , Tamanho do Órgão , Ratos , Triglicerídeos/sangueRESUMO
We've studied xymedon (30 mg/kg, 12 m) and parmidin (pyridinolcarbamate 30 mg/kg, 12 m.) effects on the development of experimental cholesterol atherosclerosis on rabbits. It was demonstrated that after the use of xymedon aorta damage reduces twice. Xymedon also prevents accumulation of cholesterol and fatty degeneration of the liver. Antiatherogenic effect of xymedon resulted comparable with the effect of parmidin. As it was demonstrated in the present investigation and in the previous ones in contrast to parmidin, xymedon normalizes the lipoproteins balance owing to increase of HDL cholesterol. It also has regenerative activity on endotheliocytes and immunomodulator properties. That can be of great importance for the anti-atherosclerotic effects of the medicine.
Assuntos
Arteriosclerose/prevenção & controle , Piridinolcarbamato/uso terapêutico , Pirimidinas/uso terapêutico , Animais , Aorta/patologia , Arteriosclerose/etiologia , Arteriosclerose/metabolismo , Arteriosclerose/patologia , Colesterol na Dieta/administração & dosagem , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Hipercolesterolemia/complicações , Hipercolesterolemia/tratamento farmacológico , Hipercolesterolemia/etiologia , Hipercolesterolemia/metabolismo , Hipercolesterolemia/patologia , Metabolismo dos Lipídeos , Lipídeos/análise , Fígado/química , Fígado/patologia , Masculino , Coelhos , Fatores de TempoRESUMO
It was shown that cimetidine (10 mg/kg, 12 weeks) reduces the frequency and the degree of affection of rabbit's aortas during experimental cholesterol atherosclerosis. The protective effect of cimetidine on the liver where the contents of lipids, especially cholesterol esters reduced considerably, was noted. The nature of the fatty dystrophy changes from the large-drop to the small-drop one which should be considered as a favourable phenomenon. The anti-atherogenic and hepatoprotective effects of cimetidine can be explained by slowing-down of lipoperoxidation processes which is proved in respect of blood and aorta walls.
